<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Krull, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eugenia Chan, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marilyn Augustyn, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Attention deficit hyperactivity disorder (ADHD) is a disorder that manifests in childhood with symptoms of hyperactivity, impulsivity and/or inattention [
         <a href="#rid1">
          1
         </a>
         ]. The symptoms affect cognitive, academic, behavioral, emotional, and social functioning.
        </p>
        <p>
         Several types of medications are available to treat ADHD in children and adolescents: stimulants, selective norepinephrine reuptake inhibitors, alpha-2-adrenergic agonists, and antidepressants  (
         <a class="graphic graphic_table graphicRef80151" href="/z/d/graphic/80151.html" rel="external">
          table 1
         </a>
         ). This topic will provide an overview of the pharmacology of medications used to treat ADHD in children and adolescents. Choosing a particular medication for an individual patient is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Choice of agent'
         </a>
         .)
        </p>
        <p>
         Other topics related to ADHD are presented separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/602.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/624.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/623.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5763.html" rel="external">
          "Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1232.html" rel="external">
          "Attention deficit hyperactivity disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          STIMULANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulant drugs include methylphenidates (
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13010" href="/z/d/drug information/13010.html" rel="external">
          dexmethylphenidate
         </a>
         ) and amphetamines (
         <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">
          dextroamphetamine
         </a>
         and mixed
         <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">
          dextroamphetamine-amphetamine
         </a>
         salts). Stimulant drugs, with or without behavioral interventions, generally are the first-line treatment for school-aged children (≥6 years) and adolescents with uncomplicated ADHD [
         <a href="#rid2">
          2
         </a>
         ]. Stimulants are controlled substances and require a schedule II prescription. Stimulants are available in short-, intermediate-, and long-acting formulations  (
         <a class="graphic graphic_table graphicRef81815 graphicRef77580" href="/z/d/graphic/81815.html" rel="external">
          table 2A-B
         </a>
         ).
        </p>
        <p>
         The exact mechanism of action of stimulants in ADHD is unknown. However, stimulants affect the dopaminergic and noradrenergic systems, causing the release of catecholamines from storage sites at the central nervous system synapses [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1220860245">
         <span class="h2">
          Methylphenidate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Short-acting
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         (eg, Ritalin, Methylin) is available as a tablet, chewable tablet, or liquid  (
         <a class="graphic graphic_table graphicRef81815" href="/z/d/graphic/81815.html" rel="external">
          table 2A
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]. Behavioral effects may be seen within 30 minutes [
         <a href="#rid5">
          5
         </a>
         ]. The duration of action is three to five hours and the half-life is two to three hours.
        </p>
        <p>
         Long-acting
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         is available in tablets, chewable tablets, oral disintegrating tablets, capsules, oral suspension, and a patch [
         <a href="#rid6">
          6-8
         </a>
         ]. The onset and duration of action vary depending upon the formulation  (
         <a class="graphic graphic_table graphicRef77580" href="/z/d/graphic/77580.html" rel="external">
          table 2B
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Single pulse wax matrix sustained release tablets (eg, Metadate-ER) have onset of action within 20 to 60 minutes and last up to 8 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osmotic release
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         tablets (eg, Concerta [brand name], Relexxii [brand name]) are coated with immediate release methylphenidate (for initial dosing) and use an osmotic pump to gradually release methylphenidate to approximate a three-times-per-day dosing schedule. Osmotic release methylphenidate usually has onset of action within 20 to 60 minutes and lasts up to 12 hours. Osmotic release methylphenidate tablets must be swallowed whole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extended release orally disintegrating tablets (Cotempla XR-ODT) contain a mixture of immediate release and extended release
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         . They have onset of action within one hour and last up to 12 hours [
         <a href="#rid8">
          8
         </a>
         ]. Although the prescribing information indicates that extended release orally disintegrating tablets should be taken consistently with or without food, we suggest that they be taken consistently with food – given the general stimulant effect of appetite suppression. (See
         <a class="local">
          'General adverse effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sustained release capsules (eg, Aptensio XR, Focalin XR, Metadate CD, Ritalin LA) contain a mixture (usually one-to-one) of immediate release and enteric-coated delayed release beads (or pearls) and generally approximate a twice-per-day dosing schedule [
         <a href="#rid9">
          9
         </a>
         ]. They typically have onset of action within 20 to 60 minutes and may last up to 12 hours. Delayed release/extended release
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         capsules (Jornay PM) contain beads within two film coatings: an outer coating that delays release for approximately 10 hours and an inner coating that controls release throughout the day [
         <a href="#rid10">
          10
         </a>
         ]. Sustained release stimulant capsules can be opened and sprinkled on soft foods.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="130955" href="/z/d/drug information/130955.html" rel="external">
          Serdexmethylphenidate-dexmethylphenidate
         </a>
         (Azstarys) capsules contain 70 percent serdexmethylphenidate (a prodrug of
         <a class="drug drug_pediatric" data-topicid="13010" href="/z/d/drug information/13010.html" rel="external">
          dexmethylphenidate
         </a>
         ) and 30 percent dexmethylphenidate (the d-enantiomer of
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ]. Dexmethylphenidate is immediately released and serdexmethylphenidate is converted to dexmethylphenidate slowly over several hours. Serdexmethylphenidate-dexmethylphenidate has an onset of action within 1 hour and may last up to 13 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The oral suspension (Quillivant XR) and chewable tablet (Quillichew ER) are a racemic mixture of the d- and l-isomers of
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         ; the d-isomer is more active. It has onset of action within one hour and lasts as long as 8 hours (Quillichew ER) or 12 hours (Quillivant XR) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         patch (Daytrana) delivers methylphenidate transdermally. The methylphenidate patch has onset of action of 60 minutes. The duration of action may be as long as 12 hours but can be controlled by early removal of the patch (the effects last approximately two to three hours after the patch is removed). The methylphenidate patch should not be cut [
         <a href="#rid12">
          12
         </a>
         ]; if a lower dose is needed a lower dose (ie, smaller) patch should be prescribed.
        </p>
        <p>
        </p>
        <p>
         The dose-response rate of
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         is highly variable, and careful dose titration is necessary within the limitations of available formulations [
         <a href="#rid13">
          13,14
         </a>
         ]. Guidelines for the initial dose and dose titration for methylphenidate preparations are provided in the tables  (
         <a class="graphic graphic_table graphicRef81815 graphicRef77580" href="/z/d/graphic/81815.html" rel="external">
          table 2A-B
         </a>
         ). We do not suggest weight-based dosing, but as a general guide, significant reduction in core symptoms (ie, hyperactivity, impulsivity, and inattention) typically occurs at doses between 0.3 and 0.6 mg/kg.
         <a class="drug drug_pediatric" data-topicid="13010" href="/z/d/drug information/13010.html" rel="external">
          Dexmethylphenidate
         </a>
         (the d-enantiomer of methylphenidate) is generally efficacious at doses approximately one-half of those needed for methylphenidate [
         <a href="#rid4">
          4,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Dose titration'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Amphetamines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amphetamines can be prescribed as a single salt (
         <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">
          dextroamphetamine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine sulfate
         </a>
         ) or as mixed
         <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">
          dextroamphetamine-amphetamine
         </a>
         salts.
         <a class="drug drug_pediatric" data-topicid="13015" href="/z/d/drug information/13015.html" rel="external">
          Lisdexamfetamine
         </a>
         is a prodrug of dextroamphetamine that is pharmacologically activated after oral ingestion and was designed to discourage drug misuse [
         <a href="#rid4">
          4,16
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          Amphetamine
         </a>
         medications for ADHD are available in immediate and sustained release preparations  (
         <a class="graphic graphic_table graphicRef81815 graphicRef77580" href="/z/d/graphic/81815.html" rel="external">
          table 2A-B
         </a>
         ). The immediate release preparations of amphetamine and
         <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">
          dextroamphetamine-amphetamine
         </a>
         are available as tablets or oral solution, and have an onset of action of 20 to 60 minutes and a reported duration of up to 6 hours  (
         <a class="graphic graphic_table graphicRef81815" href="/z/d/graphic/81815.html" rel="external">
          table 2A
         </a>
         ) [
         <a href="#rid4">
          4,17
         </a>
         ].
        </p>
        <p>
         Longer-acting preparations (6 to 13 hours) of
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">
          dextroamphetamine-amphetamine
         </a>
         are available as capsules, a liquid suspension, tablets, orally disintegrating tablets, chewable tablets, or a patch [
         <a href="#rid18">
          18-22
         </a>
         ]. The onset and duration of action vary depending upon the formulation  (
         <a class="graphic graphic_table graphicRef77580" href="/z/d/graphic/77580.html" rel="external">
          table 2B
         </a>
         ), typically ranging from 20 to 60 minutes for onset of action and at least 10 hours' duration [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sustained release capsules (eg, Adderall XR, Mydayis) contain a mixture of immediate release and enteric-coated delayed release beads (or pearls) and approximate a twice-per-day or three-times per day dosing schedule [
         <a href="#rid23">
          23
         </a>
         ]. They typically have onset of action within 20 to 60 minutes and last up to 10 hours (Adderall XR and generic) or 16 hours (Mydayis). Sustained release
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         capsules can be opened and sprinkled on soft foods.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13015" href="/z/d/drug information/13015.html" rel="external">
          Lisdexamfetamine
         </a>
         (Vyvanse) capsules or chewable tablets have onset of action within 60 minutes and lasts up to 10 hours. Capsules can be opened and dissolved in water.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyanavel extended release
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         tablets have an onset of action within 60 minutes and last up to 13 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The liquid suspension of Dyanavel extended release
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         has an onset of action within 60 minutes and lasts up to 13 hours. It should not be mixed with food or other liquids before administration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pharmacokinetics of extended release orally disintegrating
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         (Adzenys XR-ODT) suggest an onset of action within 60 minutes and duration of approximately 10 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The
         <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">
          dextroamphetamine
         </a>
         patch (Xelstrym) delivers dextroamphetamine transdermally [
         <a href="#rid22">
          22
         </a>
         ]. It has onset of action within two hours. The duration of action may be as long as 12 hours but can be controlled by early removal of the patch (the effects last for several hours after the patch is removed). The dextroamphetamine patch should not be cut; if a lower dose is needed, a lower dose (ie, smaller) patch should be prescribed.
        </p>
        <p>
        </p>
        <p>
         Guidelines for the initial dose and dose titration for
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         medications are provided in the tables  (
         <a class="graphic graphic_table graphicRef81815 graphicRef77580" href="/z/d/graphic/81815.html" rel="external">
          table 2A-B
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Stimulant adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulants have been used to treat ADHD since the 1930s [
         <a href="#rid24">
          24
         </a>
         ] and generally are considered to be safe [
         <a href="#rid25">
          25,26
         </a>
         ]. Rare, serious adverse events have been reported in children being treated with stimulants, but a causal association has not been established [
         <a href="#rid27">
          27
         </a>
         ]. The potential risks of stimulants should be discussed with patients and caregivers when choosing a treatment strategy. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Pretreatment education'
         </a>
         .)
        </p>
        <p>
         Although ADHD is common among children with epilepsy,
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         does not appear to increase the frequency or severity of seizures in children who are receiving appropriate anticonvulsant medications. (See
         <a class="medical medical_review" href="/z/d/html/129781.html" rel="external">
          "Epilepsy in children: Comorbidities, complications, and outcomes", section on 'Attention deficit hyperactivity disorder'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H44169251">
         <span class="h3">
          General adverse effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the side effects of stimulants are mild, of short duration, and reversible with adjustments to the dose or dosing interval [
         <a href="#rid2">
          2,26-29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Managing stimulant adverse effects'
         </a>
         .)
        </p>
        <p>
         The frequency of most side effects is similar with
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         and amphetamines. However, treatment with mixed
         <a class="drug drug_pediatric" data-topicid="13219" href="/z/d/drug information/13219.html" rel="external">
          dextroamphetamine-amphetamine
         </a>
         salts may be associated with greater decrease in weight over time and increased risk of irritability than treatment with methylphenidate [
         <a href="#rid30">
          30,31
         </a>
         ]. Side effects may occur more frequently in preschool children than in older children [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Relatively common side effects include appetite suppression, poor growth or weight loss during childhood, sleep disturbance, jitteriness, emotional lability, and social withdrawal [
         <a href="#rid27">
          27,33-37
         </a>
         ]. Deceleration of linear growth may occur but appears to attenuate over time; cessation of treatment may result in normalization of growth [
         <a href="#rid38">
          38-43
         </a>
         ]. Although clinical studies have suggested that adult height is not affected, average adult height was lower among participants in a randomized trial who used stimulants consistently over 16 years than in participants whose stimulant use was negligible (-4 cm [1.6 inches]) or inconsistent (-2.7 cm [1 inch]) or in a local comparison group (-3.3 cm [1.3 inches]) [
         <a href="#rid37">
          37
         </a>
         ]. At a mean age of 24.7 years, average adult weight was greater in participants with consistent stimulant use than in the local comparison group (+7.5 kg [16.5 pounds]).
        </p>
        <p>
         Growth should be regularly monitored during treatment with stimulants [
         <a href="#rid4">
          4
         </a>
         ]. Less common side effects include increased heart rate and blood pressure, headache, dizziness, gastrointestinal symptoms, priapism in males, and peripheral vasculopathy, including Raynaud phenomenon [
         <a href="#rid28">
          28,44-46
         </a>
         ].
        </p>
        <p>
         Patients treated with the
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         patch may develop contact sensitization if the patch is worn in the same location every day [
         <a href="#rid12">
          12,47
         </a>
         ]. The methylphenidate patch has also been associated with permanent loss of skin color (chemical leukoderma) [
         <a href="#rid48">
          48,49
         </a>
         ]. Among the 51 cases reported to the US Food and Drug Administration (FDA) Adverse Event Reporting System database between April 2006 and December 2014, the time to onset of leukoderma after starting the patch ranged from two months to four years. The area of depigmentation ranged up to 8 inches (20.3 cm) in diameter. In 43 cases, the loss of pigmentation was limited to the application site, but seven patients also had depigmentation in other areas. The depigmentation may be disfiguring but is not harmful. Patients who notice hypopigmentation or depigmentation should seek medical attention. The methylphenidate patch should be discontinued and the patient transitioned to another long-acting treatment  (
         <a class="graphic graphic_table graphicRef77580" href="/z/d/graphic/77580.html" rel="external">
          table 2B
         </a>
         and
         <a class="graphic graphic_table graphicRef61007" href="/z/d/graphic/61007.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H44169258">
         <span class="h3">
          Cardiovascular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse cardiovascular effects of stimulants and the cardiac evaluation for children receiving pharmacotherapy for ADHD are discussed separately. Blood pressure and heart rate should be monitored before and during treatment with stimulants [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5763.html" rel="external">
          "Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14345541">
         <span class="h3">
          Priapism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Priapism is a rare complication of
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         stimulants [
         <a href="#rid50">
          50-52
         </a>
         ]. Review of data submitted to the FDA Adverse Event Reporting System identified 15 cases of priapism in male methylphenidate recipients between 1997 and 2012 [
         <a href="#rid46">
          46
         </a>
         ]. Most of the cases occurred in males &lt;18 years (median age 12.5 years, range 8 to 33 years); two cases required surgical treatment. Priapism occurred in a variety of settings including increased dose, longer than typical dosing interval, and temporary or permanent discontinuation of methylphenidate stimulants.
        </p>
        <p>
         Priapism has also been reported among four male patients taking
         <a class="drug drug_pediatric" data-topicid="103885" href="/z/d/drug information/103885.html" rel="external">
          amphetamine
         </a>
         stimulants for ADHD [
         <a href="#rid46">
          46
         </a>
         ]. However, the correlation between amphetamine stimulants and priapism is uncertain because these patients were also taking other medications associated with priapism.
        </p>
        <p>
         The diagnosis and treatment of priapism are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6887.html" rel="external">
          "Priapism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H44169265">
         <span class="h3">
          Psychiatric effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychosis
         </strong>
         – Children and adolescents treated with stimulant medications
         <strong>
          rarely
         </strong>
         may develop psychotic symptoms (eg, hallucinations, delusional thinking, or mania), but causality has not been established [
         <a href="#rid53">
          53-56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In pooled analysis of data from 49 randomized trials of medications used to treat ADHD (35 of which evaluated stimulants), psychotic symptoms developed in 11 children during 743 person-years of follow-up (incidence rate of 1.48 episodes per 100 person-years) [
         <a href="#rid54">
          54
         </a>
         ]. In subsequent analysis of two commercial insurance claims databases that evaluated psychosis requiring treatment with antipsychotic medication after initiation of stimulant therapy in 221,846 adolescents and young adults (age 13 to 25 years), 343 episodes occurred in 143,286 person-years of follow-up (incidence rate of 2.4 episodes per 1000 person-years) [
         <a href="#rid55">
          55
         </a>
         ]. The median time between initiation of stimulant and the psychotic episode was 128 days. The absolute risk was higher with amphetamines than with
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         (2.83 versus 1.78 episodes per 1000 person-years, hazard ratio 1.7, 95% CI 1.3-2.1).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although it is not possible to predict which patients will develop psychotic symptoms after initiation of stimulants [
         <a href="#rid56">
          56
         </a>
         ], the risk may be increased in children with a family history of mental illness (eg, major depressive disorder, bipolar disorder) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suicidal thinking
         </strong>
         – Rare cases of suicidal thinking have been reported among individuals taking stimulants for ADHD, but causality has not been established [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H44169280">
         <span class="h3">
          Tics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulant medications have been reported to be associated with new onset of tics or worsening of tics in children with tic disorders [
         <a href="#rid61">
          61
         </a>
         ]. Tics or a family history of tics are included as a contraindication to some forms of
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         and may be considered a potential adverse effect of both methylphenidate and amphetamines. Nonetheless, stimulant medications often improve attention and behavior without worsening tics in children who have chronic tics or Tourette syndrome [
         <a href="#rid62">
          62-67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/126069.html" rel="external">
          "Tourette syndrome: Management", section on 'Attention deficit hyperactivity disorder'
         </a>
         .)
        </p>
        <p>
         ADHD and tic disorders frequently coexist: Approximately 20 percent of children with ADHD develop chronic tic disorders and approximately 50 percent of children with chronic tics or Tourette syndrome have comorbid ADHD [
         <a href="#rid65">
          65,68
         </a>
         ]. Given the frequency of comorbid tic disorders and ADHD and the typical waxing and waning pattern of tics, new or worsening tics in children who receive stimulant medications may be coincidentally rather than causally associated [
         <a href="#rid66">
          66,69
         </a>
         ]. In a 2015 meta-analysis of 22 randomized trials (2385 participants) comparing stimulant medications and placebo in children with ADHD, the proportion of children with new or worsening tics was similar in the stimulant and placebo groups (5.7 versus 6.5 percent, respectively; relative risk 0.99, 95% CI 0.78-1.27) [
         <a href="#rid66">
          66
         </a>
         ]. The risk of new or worsening tics was not associated with stimulant formulation, dose, duration of treatment, or patient age. Other meta-analyses evaluating the treatment of ADHD in children with comorbid tic disorders found that
         <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">
          dextroamphetamine
         </a>
         prescribed at higher than the usual recommended doses was associated with exacerbation of tics, but
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         was not [
         <a href="#rid65">
          65,67
         </a>
         ].
        </p>
        <p>
         Taken together, these findings suggest that children with tics and ADHD can benefit from stimulant medications without worsening of tics, but higher-than-usual doses of
         <a class="drug drug_pediatric" data-topicid="13218" href="/z/d/drug information/13218.html" rel="external">
          dextroamphetamine
         </a>
         should be avoided. For children in whom stimulant medications were discontinued because of new or worsening tics, resuming treatment with stimulants may be warranted, particularly if the behavioral response to nonstimulant medications was inferior to that with stimulants.
        </p>
        <p class="headingAnchor" id="H44169287">
         <span class="h3">
          Diversion and misuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulant diversion consists of the transfer of medication from the patient for whom it was prescribed to another individual [
         <a href="#rid70">
          70
         </a>
         ]. Stimulant misuse consists of taking higher doses of medication than prescribed to achieve euphoria or combining stimulant medications with illicit drugs or alcohol [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
         A systematic review of studies related to diversion and misuse of ADHD medications indicated that 5 to 9 percent of grade- and high-school-age students and 5 to 35 percent of college-age individuals reported nonprescribed stimulant use in the year before the study [
         <a href="#rid71">
          71
         </a>
         ]. The proportion of students with stimulant prescriptions who were ever asked to give, sell, or trade their medications ranged from 16 to 29 percent. Diversion and misuse were more common among White students, members of fraternities and sororities, students with lower grade point averages, and those who report ADHD symptoms. Diversion and misuse also was more common with immediate than extended release preparations. The most commonly reported reasons for stimulant diversion and misuse included studying, staying awake, improved alertness, experimenting, and "getting high."
        </p>
        <p>
         In a survey that compared diversion and misuse of psychotropic medications (eg, stimulants, selective serotonin reuptake inhibitors, tricyclic antidepressants, alpha-adrenergic agonists, etc) among 55 adolescents and young adults with ADHD and 42 adolescents and young adults with other conditions, stimulant diversion and misuse were more frequent among subjects with ADHD than with other conditions (11 versus 0 percent for diversion and 22 versus 5 percent for misuse) [
         <a href="#rid70">
          70
         </a>
         ]. All of the ADHD subjects who diverted or misused their medication had either comorbid conduct disorder or substance use disorder.
        </p>
        <p class="headingAnchor" id="H2159402">
         <span class="h2">
          Contraindications to stimulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to stimulant medications may include [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic cardiovascular disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severe hypertension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperthyroidism
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Known hypersensitivity or idiosyncrasy to sympathomimetic amines
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Motor tics or Tourette syndrome
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glaucoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agitated states
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of drug abuse
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent use or use within 14 days of the administration of monoamine oxidase inhibitors
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1197896276">
         <span class="h1">
          SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS
         </span>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Atomoxetine
         </span>
        </p>
        <p class="headingAnchor" id="H2809263239">
         <span class="h3">
          Indications and use
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         (Strattera) is a selective norepinephrine reuptake inhibitor that can be used to treat ADHD in children, adolescents, and adults [
         <a href="#rid2">
          2,72
         </a>
         ]. It is not a controlled substance [
         <a href="#rid73">
          73
         </a>
         ]. Atomoxetine is an alternative to stimulants for children (≥6 years) and adolescents who have a substance abuse problem, household member with a substance abuse problem, tics, or severe side effects with stimulants.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         is an oral capsule and can be taken once or twice per day; the capsule should be swallowed intact [
         <a href="#rid73">
          73
         </a>
         ]. When administered once daily, efficacy is better with morning than evening dosing [
         <a href="#rid74">
          74
         </a>
         ]. However, evening dosing is associated with fewer overall adverse effects than morning dosing and may be better tolerated when initiating therapy (though no specific type of adverse event is more common with morning dosing). Some side effects (eg, headache) may improve if the total daily dose is divided twice per day.
        </p>
        <p>
         The duration of action of
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         is at least 10 to 12 hours [
         <a href="#rid5">
          5,75
         </a>
         ]. In a 2013 systematic review of five randomized trials, the initial onset of action ranged from one to four weeks [
         <a href="#rid76">
          76
         </a>
         ]; full response typically was not achieved until 6 to 12 weeks. Atomoxetine must be given every day without "drug holidays" [
         <a href="#rid77">
          77
         </a>
         ]. Atomoxetine may be discontinued abruptly if a decision is made to discontinue it. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Termination of therapy'
         </a>
         .)
        </p>
        <p>
         The dose of
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         depends upon the child's weight:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children and adolescents weighing ≤70 kg should be started at a dose of 0.5 mg/kg for a minimum of three days and then titrated up to a daily dose of approximately 1.2 mg/kg in either one or two daily doses; the maximum daily dose should not exceed 1.4 mg/kg or 100 mg, whichever is less.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who weigh more than 70 kg should be started at a dose of 40 mg for a minimum of three days, followed by an increase to approximately 80 mg; after two to four weeks, the dose may be increased to a maximum of 100 mg if additional benefit is needed.
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         is metabolized through the cytochrome P450 (CYP2D6) enzyme pathway. Dose adjustments may be necessary for patients receiving drugs that are strong inhibitors of CYP2D6 (eg,
         <a class="drug drug_pediatric" data-topicid="12681" href="/z/d/drug information/12681.html" rel="external">
          paroxetine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         ) [
         <a href="#rid4">
          4,78,79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Atomoxetine adverse effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General adverse effects
         </strong>
         – Common adverse effects of
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         include weight loss, abdominal pain, decreased appetite, vomiting, nausea, dyspepsia, headache, dizziness, somnolence/fatigue, and irritability [
         <a href="#rid2">
          2,26,29,80,81
         </a>
         ]. The risk of adverse effects may be affected by genetic variations in the cytochrome P450 (CYP2D6) enzyme pathway [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular effects
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         has stimulatory effect on the sympathetic nervous system, and rare, but serious, cardiovascular events, including sudden death, may occur during treatment with atomoxetine [
         <a href="#rid73">
          73,82
         </a>
         ]. Children should be evaluated for cardiac disease before initiation of pharmacotherapy for ADHD. This evaluation is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5763.html" rel="external">
          "Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder", section on 'Pretreatment clinical evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Priapism
         </strong>
         – Priapism is a rare, but serious, adverse effect of
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         [
         <a href="#rid73">
          73
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6887.html" rel="external">
          "Priapism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Suicidal thinking
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         has a boxed warning and additional warning statements regarding the increased risk of suicidal thinking in children and adolescents treated with atomoxetine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a small number of patients,
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         has been associated with an increased risk of suicidal thinking [
         <a href="#rid83">
          83,84
         </a>
         ]. Combined analysis of 12 short-term (6 to 18 weeks) placebo-controlled trials of atomoxetine in 2208 patients (1357 of whom received atomoxetine) showed an increased risk of suicidal thinking among patients in the atomoxetine group (0.4 percent versus none of the controls; one patient in the atomoxetine group and none of the control patients attempted suicide) [
         <a href="#rid83">
          83
         </a>
         ]. In subsequent pooled analysis of data from 714 patients who were treated with atomoxetine for ≥3 years, 1.5 percent reported suicidal ideation and 0.3 percent reported suicide attempt [
         <a href="#rid84">
          84
         </a>
         ]. However, in a longitudinal register-based study that included &gt;6000 patients treated with atomoxetine and used within-patient comparisons, the risk of suicidal behavior was the same during periods of ADHD treatment with nonstimulant medication as it was during periods of no treatment (hazard ratio 0.96, 95% CI 0.72-1.30) [
         <a href="#rid85">
          85
         </a>
         ]. In a retrospective cohort of 279,315 patients (age 5 to 18 years) treated with atomoxetine or stimulants for ADHD and followed for 12 months, suicide events (suicide or suicide attempt) were rare (0.08 percent); atomoxetine was not associated with an increased risk of suicide or suicide attempt [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Children and adolescents taking
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         should be closely observed for clinical worsening, agitation, irritability, suicidal thinking or behaviors, and unusual changes in behavior, particularly during the first four to five months of therapy and when the dose is increased or decreased. The observation should include daily observation by families and caregivers and frequent contact with the prescribing clinician. Additional information for patients and health care professionals is available from the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fpostmarket-drug-safety-information-patients-and-providers%2Fatomoxetine-marketed-strattera-information&amp;token=bVMnZJtAKSstw1YviU5jv4wKAKTjlRyAiiuRIUbdaw0l7YdEUemAQwtlzo091JCDyHRIyh3t4AUDpUY7qVfQhhBPqohrxYyE%2BghQjtpLOxfQCe9%2Bb40%2FFzQw9P64iroZC0lWUBAYnplWka6WUo1jCQ%3D%3D&amp;TOPIC_ID=621" target="_blank">
          US Food and Drug Administration (FDA)
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Psychiatric effects
         </strong>
         – In addition to suicidal thinking, other rare psychiatric adverse effects may occur during treatment with
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         . These include emergence of psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania) in patients with no previous history of psychosis or mania and emergence of aggressive behavior or hostility [
         <a href="#rid73">
          73
         </a>
         ]. Patients should be screened for risk factors for bipolar disorder (eg, family or personal history of mania and depression) before initiation of atomoxetine. (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Prerequisites'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tics
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         use has been associated with the onset of motor tics [
         <a href="#rid87">
          87,88
         </a>
         ]. However, in a randomized controlled trial in 148 children and adolescents with ADHD and comorbid tic disorders, treatment with atomoxetine did not exacerbate tic symptoms compared with placebo [
         <a href="#rid89">
          89
         </a>
         ]. Two meta-analyses of studies evaluating treatment of ADHD in children with comorbid tic disorders found that atomoxetine improved ADHD behaviors without exacerbating tics [
         <a href="#rid65">
          65,67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Liver injury
         </strong>
         – Idiosyncratic severe liver injury has been reported in children and adults treated with
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         [
         <a href="#rid90">
          90-93
         </a>
         ]. Among six patients reported to the FDA, the duration of treatment before liver injury varied from 3 weeks to 730 days (median 63 days) [
         <a href="#rid93">
          93
         </a>
         ]. In one patient the evaluation was suggestive of type 1 autoimmune hepatitis, but the others had no alternative explanation for liver injury [
         <a href="#rid90">
          90
         </a>
         ]. None of the patients required liver transplantation, and most recovered after discontinuation of atomoxetine; there was one death, but it was not clear if atomoxetine caused or contributed to the death [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients taking
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         should contact their health care provider if they develop signs or symptoms of severe liver disease (eg, fatigue, anorexia, nausea, vomiting, pruritus, dark urine, jaundice, right upper quadrant tenderness, unexplained "flu-like" symptoms); liver enzymes should be measured [
         <a href="#rid93">
          93
         </a>
         ]. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury and cases of severe liver injury reported to the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fsafety%2Fmedwatch-fda-safety-information-and-adverse-event-reporting-program&amp;token=xvyaImDcLZQw%2FKZaoXWwxUDhBq6SPMBQbzrmFLdvw6uLInTYq0WEZZE23nYfEJdpji3bziSW87ksfkpGSKeZ%2FC4BVOKV%2FWdosDZdfOoBdep7W5s6oZowZkx4dccnetNU&amp;TOPIC_ID=621" target="_blank">
          FDA MedWatch program
         </a>
         [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2159581">
         <span class="h3">
          Contraindications to atomoxetine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         include [
         <a href="#rid73">
          73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypersensitivity to
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         or any component
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Concurrent use or use within 14 days of the administration of monoamine oxidase inhibitors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glaucoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current or past history of pheochromocytoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe cardiovascular disorders in which an increase in diastolic blood pressure &gt;15 mmHg, an increase in systolic blood pressure &gt;20 mmHg, or an increase in heart rate &gt;20 beats/minute would be expected to cause clinical deterioration
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1394237727">
         <span class="h2">
          Viloxazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="131245" href="/z/d/drug information/131245.html" rel="external">
          Viloxazine
         </a>
         (Qelbree) is a selective norepinephrine reuptake inhibitor that can be used to treat ADHD in children age 6 to 17 years of age [
         <a href="#rid94">
          94
         </a>
         ]. It is not a controlled substance.
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="131245" href="/z/d/drug information/131245.html" rel="external">
          Viloxazine
         </a>
         is an extended release capsule that is taken once per day. The capsule may be swallowed whole or opened to sprinkle the entire contents onto one teaspoon of applesauce. It should not be crushed, cut, or chewed. Contraindications include concomitant use or use within 14 days after discontinuing a monoamine oxidase inhibitor and concomitant use of certain CYP1A2 substrates. For additional information, refer to the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         .
        </p>
        <p>
         The recommended initial dose and titration vary with age:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         6 to 11 years – Initial dose 100 mg orally once daily; may increase by 100 mg weekly to the maximum dose of 400 mg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         12 to 17 years – Initial dose 200 mg orally once daily; may increase by 200 mg weekly to the maximum dose of 400 mg
        </p>
        <p>
        </p>
        <p>
         Clinical experience with
         <a class="drug drug_pediatric" data-topicid="131245" href="/z/d/drug information/131245.html" rel="external">
          viloxazine
         </a>
         is limited. In randomized prelicensure trials, viloxazine resulted in greater improvement from baseline on the ADHD Rating Scale, fifth edition than placebo (difference of approximately 5 to 7 points after six to eight weeks of treatment) [
         <a href="#rid94">
          94
         </a>
         ]. In one trial, symptom improvement was evident as early as week 1 of treatment [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="131245" href="/z/d/drug information/131245.html" rel="external">
          Viloxazine
         </a>
         has a boxed warning and additional warning statements regarding the increased risk of suicidal thinking in children and adolescents treated with viloxazine [
         <a href="#rid94">
          94
         </a>
         ]. In clinical trials, adverse effects included an increased risk of suicidal thoughts and behaviors compared with patients receiving placebo (0.9 versus 0.4 percent). Patients treated with viloxazine should be monitored for suicidal behavior.
        </p>
        <p>
         Other adverse effects include increased heart rate and blood pressure, somnolence, fatigue, insomnia, decreased appetite, nausea, vomiting, and irritability.
        </p>
        <p class="headingAnchor" id="H1130293854">
         <span class="h1">
          ALPHA-2-ADRENERGIC AGONISTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alpha-2-adrenergic agonists (eg, extended release
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         ) usually are reserved for children and adolescents who respond poorly to a trial of stimulants or selective norepinephrine reuptake inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         ), have unacceptable side effects with stimulants or selective norepinephrine reuptake inhibitors, or have significant comorbid conditions. Alpha-2-adrenergic agonists may take up to two weeks for initial response (compared with 20 minutes to a few hours for stimulants) and there are fewer data regarding their efficacy than for stimulants and atomoxetine [
         <a href="#rid96">
          96
         </a>
         ]. Extended-release alpha-2-adrenergic agonists are US Food and Drug Administration approved as monotherapy for ADHD or as adjuncts to stimulant medications.
        </p>
        <p class="headingAnchor" id="H1130293861">
         <span class="h2">
          Extended release clonidine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extended release
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         (KAPVAY) can be used for the treatment of ADHD or as an adjunct to stimulant therapy for the treatment of ADHD in children and adolescents aged 6 to 17 years [
         <a href="#rid97">
          97
         </a>
         ]. Clonidine is not a controlled substance and has no known potential for abuse.
        </p>
        <p>
         Extended release and immediate release
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         are not interchangeable on an mg-per-mg basis because they have different pharmacokinetic profiles.
        </p>
        <p>
         The initial dose of extended release
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         is 0.1 mg at bedtime; the dose should be titrated to response in increments of 0.1 mg at weekly intervals (maximum 0.4 mg/day). Extended release clonidine should be administered twice per day, divided equally or with the higher dose administered at bedtime [
         <a href="#rid97">
          97
         </a>
         ]. The duration of action is at least 10 to 12 hours [
         <a href="#rid5">
          5
         </a>
         ]. Discontinuation of clonidine requires tapering to prevent a rebound increase in blood pressure.
        </p>
        <p>
         In the few controlled studies that have been reported,
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         was effective in reducing symptoms in patients with ADHD but not as effective as stimulants [
         <a href="#rid98">
          98,99
         </a>
         ]. The combination of extended release clonidine and stimulant medication is also effective in reducing symptoms in children with a partial response to stimulants [
         <a href="#rid100">
          100
         </a>
         ]. Clonidine may be useful in over-aroused, easily frustrated, highly active, or aggressive individuals [
         <a href="#rid101">
          101
         </a>
         ]. Although there are few randomized controlled trials with multiple drugs, the addition of clonidine to stimulant therapy may help offset some of the common stimulant side effects.
        </p>
        <p>
         In two meta-analyses, alpha-2-adrenergic agonists were associated with improvements in ADHD symptoms and comorbid tics [
         <a href="#rid65">
          65,67
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          Clonidine
         </a>
         has been used without increased morbidity in children with ADHD and comorbid tics or Tourette syndrome [
         <a href="#rid63">
          63,65,67
         </a>
         ].
        </p>
        <p>
         Side effects of
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         include sedation, depression, bradycardia, headache, and possible hypotension [
         <a href="#rid102">
          102-104
         </a>
         ]. Oral clonidine may cause generalized rash, urticaria, or angioedema in patients with a history of hypersensitivity reactions to transdermal clonidine [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1130293868">
         <span class="h2">
          Extended release guanfacine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extended release
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         (Intuniv) can be used for once-daily treatment of ADHD or as an adjunct to stimulant therapy in children and adolescents aged 6 to 17 years [
         <a href="#rid105">
          105-110
         </a>
         ]. Guanfacine has a longer half-life and fewer side effects than does
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         .
        </p>
        <p>
         Extended release and immediate release
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         are not interchangeable on an mg-per-mg basis because of differences in bioavailability.
        </p>
        <p>
         Extended release
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         is administered once per day [
         <a href="#rid5">
          5
         </a>
         ]. It can be administered in the morning or the evening, whichever is best for the patient and caregiver [
         <a href="#rid111">
          111
         </a>
         ]. The initial dose is 1 mg per day; the dose should be titrated to response in increments of 1 mg at weekly intervals (typical maximum 4 mg/day; a maximum dose of 7 mg/day may be used for adolescents &gt;12 years who weigh &gt;58.5 kg [129 pounds], but this dose may be associated with somnolence) [
         <a href="#rid112">
          112,113
         </a>
         ]. The duration of action is at least 10 to 12 hours. Extended release guanfacine requires one to two weeks for initial response. Discontinuation of guanfacine requires tapering by ≤1 mg every three to seven days to prevent a rebound increase in blood pressure [
         <a href="#rid114">
          114
         </a>
         ]. During the taper, blood pressure and heart rate should be monitored [
         <a href="#rid114">
          114
         </a>
         ].
        </p>
        <p>
         In a randomized trial in 345 patients (6 to 17 years), extended release
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         was efficacious in improving ADHD symptoms compared with placebo (reduction in ADHD-Rating Scale-IV [ADHD-RS-IV] score of 16.7 versus 9.7 points); adverse effects included headache, fatigue, abdominal pain, and sedation [
         <a href="#rid115">
          115
         </a>
         ]. Additional randomized trials support the efficacy of guanfacine compared with placebo in improving symptoms in children and adolescents with ADHD and with ADHD and comorbid oppositional defiant disorder [
         <a href="#rid108">
          108,109,116
         </a>
         ].
        </p>
        <p>
         In randomized trials comparing extended release
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         , extended release guanfacine alone, and methylphenidate alone, the combination of guanfacine and methylphenidate was well-tolerated but provided only small but significant improvements in ADHD symptoms compared with monotherapy [
         <a href="#rid117">
          117
         </a>
         ]; the combination of guanfacine and methylphenidate improved working memory compared with guanfacine alone but was not superior to methylphenidate alone and did improve other cognitive domains [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         In two meta-analyses, alpha-2-adrenergic agonists were associated with improvements in ADHD symptoms and comorbid tics [
         <a href="#rid65">
          65,67
         </a>
         ].
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          Guanfacine
         </a>
         has been used in open or small trials to treat children with ADHD and Tourette syndrome whose tics worsened with stimulants or in whom
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         was poorly tolerated (either because of its sedative side effects or short duration) [
         <a href="#rid65">
          65,67,119,120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          ANTIDEPRESSANTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antidepressants that have been used in the treatment of ADHD include tricyclic antidepressants (
         <a class="drug drug_pediatric" data-topicid="13376" href="/z/d/drug information/13376.html" rel="external">
          imipramine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13210" href="/z/d/drug information/13210.html" rel="external">
          desipramine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12653" href="/z/d/drug information/12653.html" rel="external">
          nortriptyline
         </a>
         ), and dopamine reuptake inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="12719" href="/z/d/drug information/12719.html" rel="external">
          bupropion
         </a>
         ). These medications usually are reserved for children and adolescents who respond poorly to a trial of stimulants or selective norepinephrine reuptake inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         ) or have unacceptable side effects. Antidepressants are not US Food and Drug Administration approved for treatment of ADHD but can be used to treat comorbid anxiety or depression [
         <a href="#rid121">
          121
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1130293643">
         <span class="h2">
          Tricyclic antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tricyclic antidepressants inhibit the reuptake of norepinephrine and serotonin. With the availability additional nonstimulant medications, tricyclic antidepressants usually are reserved for children and adolescents who respond poorly to a trial of stimulants, selective norepinephrine reuptake inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         ), or alpha-2-adrenergic agonists; have unacceptable side effects with these medications; or have significant comorbid conditions.
        </p>
        <p>
         A 2014 systematic review identified six randomized trials comparing tricyclic antidepressants with placebo for the treatment of ADHD in 216 children and adolescents (five trials used
         <a class="drug drug_pediatric" data-topicid="13210" href="/z/d/drug information/13210.html" rel="external">
          desipramine
         </a>
         ; one used
         <a class="drug drug_pediatric" data-topicid="12653" href="/z/d/drug information/12653.html" rel="external">
          nortriptyline
         </a>
         ) [
         <a href="#rid122">
          122
         </a>
         ]. In a meta-analysis of three trials (125 participants), treatment with tricyclic antidepressants improved core ADHD symptoms (odds ratio 18.5, 95% CI 6.3-54.4). In one trial (68 participants), desipramine was more efficacious than
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         in reducing ADHD symptoms. An earlier systematic review of four trials comparing tricyclic antidepressants with
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         found either no difference in response or slightly better results with methylphenidate [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
         Tricyclic antidepressants have been associated with adverse cardiovascular events. The 2014 systematic review found mild increases in diastolic blood pressure and pulse rates, appetite suppression (with
         <a class="drug drug_pediatric" data-topicid="13210" href="/z/d/drug information/13210.html" rel="external">
          desipramine
         </a>
         ), and increased weight gain (with
         <a class="drug drug_pediatric" data-topicid="12653" href="/z/d/drug information/12653.html" rel="external">
          nortriptyline
         </a>
         ) [
         <a href="#rid122">
          122
         </a>
         ]. Additional side effects that may limit the usefulness of tricyclic antidepressants include anticholinergic effects (eg, dry mouth, constipation, urinary retention), fatigue, and lowering of the seizure threshold [
         <a href="#rid25">
          25,122
         </a>
         ].
        </p>
        <p>
         Before tricyclic antidepressants are used to treat ADHD in children, a review of the patient's history (for heart disease and symptoms including palpitations, dizziness, syncope, or near syncope) and family history (for sudden unexpected death at less than 40 years, long QT syndrome or other arrhythmias, and hypertrophic cardiomyopathy) should be obtained [
         <a href="#rid124">
          124
         </a>
         ]. In addition, an electrocardiogram should be obtained at baseline and when the dose has been optimized because tricyclic antidepressants can cause arrhythmia [
         <a href="#rid124">
          124,125
         </a>
         ]. In children with resting heart rate ≥130 beats/min, PR interval &gt;200 millisec, QRS &gt;120 millisec, QTc &gt;460 millisec, or symptoms such as palpitations, syncope, or near syncope [
         <a href="#rid124">
          124,125
         </a>
         ], treatment with drugs other than tricyclic antidepressants and/or pediatric cardiology consultation may be indicated.
        </p>
        <p class="headingAnchor" id="H1130293658">
         <span class="h2">
          Bupropion
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="12719" href="/z/d/drug information/12719.html" rel="external">
          Bupropion
         </a>
         , an antidepressant that blocks the reuptake of norepinephrine and dopamine, has more stimulant properties than the tricyclic antidepressants [
         <a href="#rid126">
          126
         </a>
         ]. It is of modest efficacy in decreasing hyperactivity and aggressive behavior [
         <a href="#rid126">
          126
         </a>
         ]. Adverse effects include irritability, anorexia, insomnia, motor tics, and a decreased seizure threshold (at doses greater than 450 mg/day) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          INVESTIGATIONAL DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Drugs being investigated for the treatment of ADHD include cholinesterase inhibitors (tacrine,
         <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">
          donepezil
         </a>
         ) and nicotinic analogues (ABT-418) [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
         In controlled trials,
         <a class="drug drug_pediatric" data-topicid="13066" href="/z/d/drug information/13066.html" rel="external">
          modafinil
         </a>
         (Sparlon, marketed as Provigil), another stimulant, appeared to improve the core symptoms of ADHD compared with placebo [
         <a href="#rid128">
          128-130
         </a>
         ]. However, it was associated with serious dermatologic and psychiatric reactions (eg, Stevens Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, anxiety, mania, hallucinations, suicidal ideation) [
         <a href="#rid128">
          128-131
         </a>
         ]. It is not approved for use in children for any indication [
         <a href="#rid131">
          131
         </a>
         ]; the US Food and Drug Administration's Pediatrics Advisory Committee has unanimously recommended that the label include language that specifically warns against its use in children [
         <a href="#rid132">
          132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H195054031">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117871.html" rel="external">
          "Society guideline links: Attention deficit hyperactivity disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H36">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/85728.html" rel="external">
          "Patient education: Medicines for attention deficit hyperactivity disorder (ADHD) in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/1210.html" rel="external">
          "Patient education: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/1195.html" rel="external">
          "Patient education: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H37">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stimulants
         </strong>
         – Stimulant drugs include
         <a class="drug drug_pediatric" data-topicid="12600" href="/z/d/drug information/12600.html" rel="external">
          methylphenidate
         </a>
         and amphetamines. Stimulants are controlled substances and require a schedule II prescription. Stimulants are available in short-, intermediate-, and long-acting formulations  (
         <a class="graphic graphic_table graphicRef81815 graphicRef77580" href="/z/d/graphic/81815.html" rel="external">
          table 2A-B
         </a>
         ). (See
         <a class="local">
          'Stimulants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Stimulants generally are considered safe, with mild, reversible, and manageable side effects. However, there have been rare reports of serious adverse events, including sudden unexpected death, priapism, psychosis, and suicidal thinking. The potential risks of stimulants should be discussed with patients and caregivers when choosing a management strategy. (See
         <a class="local">
          'Stimulant adverse effects'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Pretreatment education'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selective norepinephrine reuptake inhibitors
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          Atomoxetine
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="131245" href="/z/d/drug information/131245.html" rel="external">
          viloxazine
         </a>
         are selective norepinephrine reuptake inhibitors. They are not controlled substances. Atomoxetine generally is considered safe, but there have been rare reports of serious adverse effects, including liver injury and an increased risk of suicidal thinking. Clinical experience with viloxazine is limited. (See
         <a class="local">
          'Selective norepinephrine reuptake inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alpha-2 adrenergic agonists and antidepressants
         </strong>
         – Alpha-2-adrenergic agonists (eg,
         <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">
          clonidine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">
          guanfacine
         </a>
         ) and antidepressants (eg, tricyclic antidepressants,
         <a class="drug drug_pediatric" data-topicid="12719" href="/z/d/drug information/12719.html" rel="external">
          bupropion
         </a>
         ) usually are reserved for children or adolescents who respond poorly to a trial of stimulants or selective norepinephrine reuptake inhibitors (eg,
         <a class="drug drug_pediatric" data-topicid="13048" href="/z/d/drug information/13048.html" rel="external">
          atomoxetine
         </a>
         ), have unacceptable side effects with stimulants or atomoxetine, or have significant comorbid conditions that can be treated directly with these medications. (See
         <a class="local">
          'Alpha-2-adrenergic agonists'
         </a>
         above and
         <a class="local">
          'Antidepressants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choosing a medication –
         </strong>
         Choosing a particular medication for an individual patient is discussed separately  (
         <a class="graphic graphic_table graphicRef80151" href="/z/d/graphic/80151.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/16927.html" rel="external">
          "Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications", section on 'Choice of agent'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          American Psychiatric Association. Attention-deficit/hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association, Washington, DC 2022. p.68.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009; 48:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drugs for ADHD. Med Lett Drugs Ther 2015; 57:37.
          </a>
         </li>
         <li class="breakAll">
          Quillivant XR prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/202100lbl.pdf (Accessed on November 15, 2012).
         </li>
         <li class="breakAll">
          Quillichew ER (methyphenidate hydrochloride) extended-release chewable tablets. US Food &amp; Drug Administration (FDA) approved product information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207960s000lbl.pdf (Accessed on December 15, 2015).
         </li>
         <li class="breakAll">
          Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets). US Food &amp; Drug Administration (FDA) approved product information. Revised June, 2017. US Food &amp; Drug Administration. Available online http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on June 22, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aptensio XR--another long-acting methylphenidate. Med Lett Drugs Ther 2015; 57:101.
          </a>
         </li>
         <li class="breakAll">
          Jornay PM (methylphenidate hydrochloride) extended release capsules. United States Prescribing Information. August 2018. US Food &amp; Drug Administration. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
         </li>
         <li class="breakAll">
          Azstarys (serdexmethylphenidate and dexmethylphenidate capsules) [package insert]. Grand Rapids, MI: Corium, Inc; 2021.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am 2011; 58:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill P, Taylor E. An auditable protocol for treating attention deficit/hyperactivity disorder. Arch Dis Child 2001; 84:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ding YS, Fowler JS, Volkow ND, et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmacology (Berl) 1997; 131:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blick SK, Keating GM. Lisdexamfetamine. Paediatr Drugs 2007; 9:129.
          </a>
         </li>
         <li class="breakAll">
          Evekeo (amphetamine sulfate tablets). US Food and Drug Administration (FDA) approved product information. Revised October 2019. US National Library of Medicine. Available online at: https://dailymed.nlm.nih.gov/dailymed (Accessed on April 20, 2021).
         </li>
         <li class="breakAll">
          Dyanavel XR (amphetamine) extended-release oral suspension. US Food &amp; Drug Administration (FDA) approved product information. US National Library of Medicine. http://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on October 29, 2015).
         </li>
         <li class="breakAll">
          Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablet. US Food &amp; Drug Administration (FDA) approved product information. US National Library of Medicine http://dailymed.nlm.nih.gov/dailymed/about.cfm (Accessed on April 04, 2016).
         </li>
         <li class="breakAll">
          Vyvanse (lisdexamfetamine dimesylate). US Food &amp; Drug Administration (FDA) approved product information. Revised February, 2017. US Food &amp; Drug Administration http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on February 03, 2017).
         </li>
         <li class="breakAll">
          Dyanavel XR (amphetamine) extended-release package insert. Tris Pharma, Inc; 2021 https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210526s000lbl.pdf (Accessed on November 17, 2021).
         </li>
         <li class="breakAll">
          Xelstrym (dextroamphetamine) transdermal system [package insert]. Miami, FL: Noven Pharmaceuticals, Inc; 2022.
         </li>
         <li class="breakAll">
          Mydayis (mixed salts of a single-entity amphetamine product) extended-release capsules. US Food &amp; Drug Administration (FDA) approved product information. June, 2017. US Food &amp; Drug Administration. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on June 22, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937; 94:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention-deficit-hyperactivity disorder. N Engl J Med 1999; 340:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clavenna A, Bonati M. Safety of medicines used for ADHD in children: a review of published prospective clinical trials. Arch Dis Child 2014; 99:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storebø OJ, Pedersen N, Ramstad E, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Cochrane Database Syst Rev 2018; 5:CD012069.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration. Drug Safety Labeling Changes June 2013. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm359843.htm?source=govdelivery (Accessed on July 15, 2013).
         </li>
         <li class="breakAll">
          Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents, Kemper AR, Maslow GR, Hill S, Namdari B, Allen LaPointe NM, Goode AP, Coeytaux RR, Befus D, Kosinski AS, Bowen SE, McBroom AJ, Lallinger KR, Sanders GD. (Eds), Agency for Healthcare Research and Quality (US), Rockville (MD) 2018.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pliszka SR, Matthews TL, Braslow KJ, Watson MA. Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, et al. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. J Clin Psychiatry 2017; 78:e648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firestone P, Musten LM, Pisterman S, et al. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998; 8:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenhill L, Kollins S, Abikoff H, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006; 45:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidwell KM, Van Dyk TR, Lundahl A, Nelson TD. Stimulant Medications and Sleep for Youth With ADHD: A Meta-analysis. Pediatrics 2015; 136:1144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Punja S, Shamseer L, Hartling L, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2016; 2:CD009996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coghill DR, Banaschewski T, Nagy P, et al. Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. CNS Drugs 2017; 31:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenhill LL, Swanson JM, Hechtman L, et al. Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2020; 59:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer JR, Loney J, Ponto LB, et al. Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems. J Am Acad Child Adolesc Psychiatry 2000; 39:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46:1015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr 2010; 157:635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harstad EB, Weaver AL, Katusic SK, et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics 2014; 134:e935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yackobovitch-Gavan M, Mimouni-Bloch A, Gabbay U, et al. Sex-Specific Long-Term Height and Body Mass Index Trajectories of Children Diagnosed with Attention-Deficit/Hyperactivity Disorder and Treated with Stimulants. J Pediatr 2021; 238:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. J Clin Rheumatol 2008; 14:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu ZJ, Parker-Kotler C, Tran K, et al. Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2010; 12:111.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns of rare risk of long-lasting erections in males taking methylphenidate ADHD medications and has approved label changes. www.fda.gov/downloads/Drugs/DrugSafety/UCM378835.pdf (Accessed on December 18, 2013).
         </li>
         <li class="breakAll">
          Daytrana prescribing information. Available at http://pi.shirecontent.com/PI/PDFs/Daytrana_USA_ENG.pdf (Accessed on August 31, 2010).
         </li>
         <li class="breakAll">
          US Food and Drug Administration. FDA drug safety communication: FDA reporting permanent skin color changes associated with use of Daytrana patch (methylphenidate transdermal system) for treating ADHD www.fda.gov/Drugs/DrugSafety/ucm452244.htm (Accessed on June 30, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghasri P, Gattu S, Saedi N, Ganesan AK. Chemical leukoderma after the application of a transdermal methylphenidate patch. J Am Acad Dermatol 2012; 66:e237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol 2013; 9:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cakin-Memik N, Yildiz O, Sişmanlar SG, et al. Priapism associated with methylphenidate: a case report. Turk J Pediatr 2010; 52:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Pediatr 2004; 144:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2006; 163:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosholder AD, Gelperin K, Hammad TA, et al. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 2009; 123:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moran LV, Ongur D, Hsu J, et al. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD. N Engl J Med 2019; 380:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortese S. Psychosis during Attention Deficit-Hyperactivity Disorder Treatment with Stimulants. N Engl J Med 2019; 380:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacKenzie LE, Abidi S, Fisher HL, et al. Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness. Pediatrics 2016; 137.
          </a>
         </li>
         <li class="breakAll">
          Health Canada. Summary Safety Review - Amphetamines - Suicidal Thought and Behaviors (Suicidality). www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/amphetamines-eng.php (Accessed on March 31, 2015).
         </li>
         <li class="breakAll">
          Health Canada. Summary Safety Review - Methylphenidate - Suicidal Thoughts and Behavior (Suicidality). www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/methylphenidate-eng.php (Accessed on March 31, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Man KKC, Coghill D, Chan EW, et al. Association of Risk of Suicide Attempts With Methylphenidate Treatment. JAMA Psychiatry 2017; 74:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denckla MB, Bemporad JR, MacKay MC. Tics following methylphenidate administration. A report of 20 cases. JAMA 1976; 235:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995; 52:444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nass R, Bressman S. Attention deficit hyperactivity disorder and Tourette syndrome: what's the best treatment? Neurology 2002; 58:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen SC, Mulqueen JM, Ferracioli-Oda E, et al. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. J Am Acad Child Adolesc Psychiatry 2015; 54:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2018; 6:CD007990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spencer T, Biederman J, Harding M, et al. Disentangling the overlap between Tourette's disorder and ADHD. J Child Psychol Psychiatry 1998; 39:1037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res 2009; 67:497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Gignac M, Swezey A, et al. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 2006; 45:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21.
          </a>
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: Diagnosis and management. Updated Septemver 2019 https://www.nice.org.uk/guidance/ng87 (Accessed on January 08, 2020).
         </li>
         <li class="breakAll">
          Strattera (atomoxetine) capsules for oral use. US Food and Drug Administration (FDA) approved product information. Revised January, 2022, US National Library of Medicine. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021411s050lbl.pdf (Accessed on January 11, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. Clin Pediatr (Phila) 2009; 48:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005; 90 Suppl 1:i26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol 2014; 28:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schonwald A. Update: attention deficit/hyperactivity disorder in the primary care office. Curr Opin Pediatr 2005; 17:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drugs for treatment of ADHD. Treat Guidel Med Lett 2006; 4:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 2014; 53:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed VA, Buitelaar JK, Anand E, et al. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research. CNS Drugs 2016; 30:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajesh AS, Bates G, Wright JG. Atomoxetine-induced electrocardiogram changes. Arch Dis Child 2006; 91:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008; 47:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009; 48:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Q, Sjölander A, Runeson B, et al. Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014; 348:g3769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linden S, Bussing R, Kubilis P, et al. Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee TS, Lee TD, Lombroso PJ, King RA. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43:1068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ledbetter M. Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 2005; 15:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005; 65:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim JR, Faught PR, Chalasani NP, Molleston JP. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006; 148:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stojanovski SD, Casavant MJ, Mousa HM, et al. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 2007; 45:51.
          </a>
         </li>
         <li class="breakAll">
          Atomoxetine (marketed as Strattera) serious liver injury. FDA Drug Safety Newsletter 2009. www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm110235.htm (Accessed on December 02, 2011).
         </li>
         <li class="breakAll">
          Qelbree (viloxazine extended release capsules). US Food and Drug Administration (FDA) approved product information. Revised April, 2022. US National Library of Medicine. Available online at https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on February 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasser A, Liranso T, Adewole T, et al. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clin Ther 2020; 42:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366:237.
          </a>
         </li>
         <li class="breakAll">
          KAPVAY (clonidine hydrochloride) extended-release tablets prescribing information. Shionogi Pharma, Inc. Atlanta, GA 2010. www.kapvay.com/Kapvay_final_09.28.10.pdf (Accessed on December 02, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palumbo DR, Sallee FR, Pelham WE Jr, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011; 127:e1406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23 Suppl 1:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42:886.
          </a>
         </li>
         <li class="breakAll">
          FDA Approved Drug Products www.accessdata.fda.gov/Scripts/cder/DrugsatFDA (Accessed on May 20, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012; 51:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cutler AJ, Brams M, Bukstein O, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2014; 53:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Robertson B, Sikirica V, et al. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newcorn JH, Harpin V, Huss M, et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry 2016; 57:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry 2013; 52:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol 2014; 24:1861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bello NT. Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents. Patient Prefer Adherence 2015; 9:877.
          </a>
         </li>
         <li class="breakAll">
          Intuniv (guanfacine) extended-release tablets, for oral use. United States Prescribing Information. Revised November, 2017. US Food &amp; Drug Administration. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on November 29, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121:e73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newcorn JH, Huss M, Connor DF, et al. Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. J Dev Behav Pediatr 2020; 41:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCracken JT, McGough JJ, Loo SK, et al. Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry 2016; 55:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilder RM, Loo SK, McGough JJ, et al. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry 2016; 55:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbaresi WJ, Campbell L, Diekroger EA, et al. The Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder: Process of Care Algorithms. J Dev Behav Pediatr 2020; 41 Suppl 2S:S58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Otasowie J, Castells X, Ehimare UP, Smith CH. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2014; :CD006997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jadad AR, Boyle M, Cunningham C, et al. Treatment of attention-deficit/hyperactivity disorder. Evid Rep Technol Assess (Summ) 1999; :i.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutgesell H, Atkins D, Barst R, et al. AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999; 38:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35:1491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996; 35:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman J, Spencer T. Non-stimulant treatments for ADHD. Eur Child Adolesc Psychiatry 2000; 9 Suppl 1:I51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005; 116:e777.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006; 67:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008; 152:394.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. 2007 Safety Alerts for Drugs, Biologics, Medical Devices, and Dietary Supplements www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152701.htm (Accessed on December 02, 2011).
         </li>
         <li class="breakAll">
          Provigil label: Panel’s “not recommended” language could be template. In: "The Pink Sheet" FDC Reports, Chevy Chase, MD, December 10, 2007. p.12.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 621 Version 80.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American Psychiatric Association. Attention-deficit/hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, American Psychiatric Association, Washington, DC 2022. p.68.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31570648" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8714313" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Catecholamines in attention-deficit hyperactivity disorder: current perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19242289" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25758544" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Drugs for ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25758544" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Drugs for ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25758544" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Drugs for ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25758544" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Drugs for ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26204039" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Aptensio XR--another long-acting methylphenidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26204039" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aptensio XR--another long-acting methylphenidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26204039" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Aptensio XR--another long-acting methylphenidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21281851" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11316683" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : An auditable protocol for treating attention deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10628897" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pharmacokinetics and clinical effectiveness of methylphenidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9181638" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and L-threo-methylphenidate in the human and baboon brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407369" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lisdexamfetamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The behavior of children receiving benzedrine
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10072414" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Treatment of attention-deficit-hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24748641" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Safety of medicines used for ADHD in children: a review of published prospective clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29744873" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29744873" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29744873" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16670648" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28682529" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9639076" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17023867" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26598454" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Stimulant Medications and Sleep for Youth With ADHD: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26844979" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28667569" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31421233" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10761355" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Predictors of adult height and weight in boys treated with methylphenidate for childhood behavior problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667480" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Effects of stimulant medication on growth rates across 3 years in the MTA follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18580502" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of stimulants on height and weight: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20605163" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25180281" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : ADHD, stimulant treatment, and growth: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34293373" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Sex-Specific Long-Term Height and Body Mass Index Trajectories of Children Diagnosed with Attention-Deficit/Hyperactivity Disorder and Treated with Stimulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18431096" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Methylphenidate and dextroamphetamine-induced peripheral vasculopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425295" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425295" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425295" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20425295" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Peripheral vasculopathy associated with psychostimulant treatment in children with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22583724" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Chemical leukoderma after the application of a transdermal methylphenidate patch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22552161" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Methylphenidate-induced erections in a prepubertal child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21043394" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Priapism associated with methylphenidate: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15127013" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Stuttering priapism associated with withdrawal from sustained-release methylphenidate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816217" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19171629" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893533" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30893541" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Psychosis during Attention Deficit-Hyperactivity Disorder Treatment with Stimulants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719291" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719291" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26719291" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28746699" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Association of Risk of Suicide Attempts With Methylphenidate Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1061848" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Tics following methylphenidate administration. A report of 20 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7771914" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865128" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Treatment of ADHD in children with tics: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11865123" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Attention deficit hyperactivity disorder and Tourette syndrome: what's the best treatment?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19625978" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26299294" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29944175" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9804036" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Disentangling the overlap between Tourette's disorder and ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19913654" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Clinical course of Tourette syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16601645" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174822" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174822" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174822" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19420182" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15665154" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23438503" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15800424" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Update: attention deficit/hyperactivity disorder in the primary care office.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17242628" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17039210" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Drugs for treatment of ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24472252" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27290715" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17119076" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Atomoxetine-induced electrocardiogram changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18176331" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20040824" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24942388" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27244795" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15322408" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Atomoxetine and tics in ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15910218" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Atomoxetine use associated with onset of a motor tic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16380617" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16769398" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Severe liver injury after initiating therapy with atomoxetine in two children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18366245" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17357382" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Atomoxetine-induced hepatitis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17357382" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Atomoxetine-induced hepatitis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17357382" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Atomoxetine-induced hepatitis in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32723670" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16023516" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Attention-deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16023516" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Attention-deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10596256" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182963" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21555501" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17581453" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19621977" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182964" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12874489" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12874489" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22176941" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25245353" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26506582" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19106767" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26871297" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23972694" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25453486" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26170637" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26170637" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166547" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32482970" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27453079" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27453080" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7559307" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11431228" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31996578" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder: Process of Care Algorithms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25238582" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10790990" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Treatment of attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10434498" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8936916" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8885585" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Bupropion hydrochloride in attention deficit disorder with hyperactivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11140780" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Non-stimulant treatments for ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16322134" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16426100" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280848" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
